Diprivan is an intravenous sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation.
Fresenius Kabi USA president and CEO John Ducker said the Diprivan 10mL dose is designed with consideration for common dosing practices to support single patient use and reduce waste.
"This is particularly important for outpatient surgery centers where lower doses are commonly administered," Ducker said.
Currently, the drug is offered in 10mL, 20mL, 50mL, and 100mL doses, making Fresenius Kabi the only company to provide customers this range of propofol doses.
The company said that Diprivan Injectable Emulsion is contraindicated in patients with a known hypersensitivity to Diprivan Injectable Emulsion or any of its components, and also in patients with allergies to eggs, egg products, soybeans or soy products.
Use of this drug has been related with both fatal and life-threatening anaphylactic and anaphylactoid reactions, as well as Propofol Infusion Syndrome.
For general anesthesia or MAC sedation, Diprivan should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure.
For sedation of intubated, mechanically ventilated patients in the ICU, the drug should be administered only by persons skilled in the management of critically ill patients and trained in cardiovascular resuscitation and airway management and these sedated patients should be continuously monitored.